Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus

Author： Kanazawa I.   Yamaguchi T.   Yano S.   Yamamoto M.   Yamauchi M.   Kurioka S.   Sugimoto T.  

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.21, Iss.12, 2010-12, pp. : 2013-2018

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Type 2 diabetes mellitus and bone

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 283, Iss. 2, 2018-02 ,pp. : 140-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone

By  

Current Drug Safety, Vol. 5, Iss. 3, 2010-07 ,pp. : 234-244

Bentham Science Publishers

Access to resources Recommend Favorite

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study

By Hanefeld M.   Pfützner A.   Forst T.   Lübben G.  

Current Medical Research and Opinion, Vol. 22, Iss. 6, 2006-06 ,pp. : 1211-1215

Informa Healthcare

Access to resources Recommend Favorite

Bone structure and turnover in type 2 diabetes mellitus

By Shu A.  

Osteoporosis International, Vol. 23, Iss. 2, 2012-02 ,pp. : 635-641

Springer Publishing Company

Access to resources Recommend Favorite

Treatment intensification in type 2 diabetes mellitus and obesity

By Zawiejska Agnieszka   McAleese Jane   Yemparala Prasad   Taheri Shahrad  

British Journal of General Practice, Vol. 63, Iss. 609, 2013-04 ,pp. : 182-182

Royal College of General Practitioners

Access to resources Recommend Favorite